Divalproex Sodium Tablet, Delayed Release
Product Images NDC 71610-032

7 FDA label images from Aphena Pharma Solutions - Tennessee, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71610-032). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 500mg (71610 032 53)

Bottle Label 500mg (71610 032 53)
Label for Divalproex Sodium Delayed-Release 500 mg tablets, containing 60 tablets. The label shows the product name, strength, and quantity along with storage instructions and manufacturer information, including Upsher-Smith Laboratories Inc., Minneapolis, MN, and repackaging by Aphena Pharma Solutions, Cookeville, TN. The NDC number 71610-0032-53 is also displayed.*
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Chemical Structure (Divalproex 01)

Chemical Structure (Divalproex 01)
Chemical structure diagram of divalproex sodium, showing its molecular components including sodium ion and organic groups with carbon, hydrogen, and oxygen atoms arranged in the characteristic structure of divalproex sodium.*
FDA Label Image

Figure 1 (Divalproex 02)

Figure 1 (Divalproex 02)
A bar chart comparing percentages between PBO (placebo) and DVPX (Divalproex Sodium) groups in two studies. Study 1 (YMRS) shows 26% for PBO and 60% for DVPX. Study 2 (MRS) shows 29% for PBO and 58% for DVPX. The y-axis represents percentage from 0% to 70%.*
FDA Label Image

Figure 2 (Divalproex 03)

Figure 2 (Divalproex 03)
A cumulative distribution curve chart comparing the percentage reduction in CPS rate for patients treated with Divalproex sodium delayed-release tablets USP versus placebo. The x-axis represents the percentage of patients, and the y-axis shows the percent reduction in CPS rate, with an indication of improvement versus worsening.*
FDA Label Image

Figure 3 (Divalproex 04)

Figure 3 (Divalproex 04)
A chart showing the percentage reduction in CPS rate versus the percentage of patients, comparing effects of high dose and low dose treatments. The vertical axis ranges from -100% (worsening) to 100% (improvement), while the horizontal axis displays percent of patients from 0 to 100. Two lines represent high dose (solid) and low dose (dashed) data trends.*
FDA Label Image

Figure 4 (Divalproex 05)

Figure 4 (Divalproex 05)
A bar chart comparing two groups labeled Placebo and Divalproex Sodium within two separate studies (Study 1 and Study 2). The chart shows a vertical axis with values from 0 to 6. In both studies, the Placebo group has higher bar values than the Divalproex Sodium group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.